GlobalData's Pharmaceutical Intelligence Center released a list predicting what the best-selling drugs will be in 2025, according to EndPoints News.
Topping the list is Keytruda, Merck's cancer immunotherapy, which GlobalData anticipates will reach $22.2 billion in sales by 2025.
Here is the full list:
1. Keytruda ($22.2 billion)
2. Eliquis ($18.7 billion)
3. Revlimid ($12.4 billion)
4. Opdivo ($12 billion)
5. Imbruvica ($11.9 billion)
6. Humira ($10.3 billion)
7. Biktarvy ($10 billion)
8. Ibrance ($9 billion)
9. Stelara ($7.5 billion)
10. Trulicity ($7.2 billion)